Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 11,734 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level A Clear all
Recruiting Phase 1 Interventional

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

NCT05698524
View directory record Official record
Conditions
Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma
Interventions
PCI 24781, Temozolomide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Enrolling by invitation Phase 4 Interventional

Titanium vs. PEEK Fusion Devices in 1 Level TLIF

NCT05691062
View directory record Official record
Conditions
Spine Fusion, Lumbar Spondylolisthesis, Lumbar Stenosis
Interventions
Titanium Fusion Device, PEEK Fusion Device
Device
Lead sponsor
Twin Cities Spine Center
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Moderate to Severe Refractory Crohn's Disease

NCT06721962
View directory record Official record
Conditions
Crohns Disease
Interventions
TRX103, Cyclophosphamide
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

NCT05511025
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Placebo, Acetaminophen
Drug · Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Phase 1 Interventional

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

NCT02244489
View directory record Official record
Conditions
Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Momelotinib (MMB), Capecitabine, Oxaliplatin
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT03223610
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Interventions
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Revlimid (lenalidomide)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

NCT01075113
View directory record Official record
Conditions
Liver Cancer
Interventions
sorafenib tosylate, vorinostat
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

NCT00002924
View directory record Official record
Conditions
Prostate Cancer
Interventions
mutation analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
49
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 21, 2026, 6:40 PM EDT
Active, not recruiting Phase 4 Interventional Results available

Use of the LEVA® Pelvic Health System for Fecal Incontinence

NCT06152224
View directory record Official record
Conditions
Fecal Incontinence
Interventions
The Leva Pelvic Health System
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Early Phase 1 Interventional

Exercising Our ABC's (African- American Breast Cancer Survivors)

NCT01684579
View directory record Official record
Conditions
Breast Cancer
Interventions
Resistance Exercise, Aerobic Exercise, Behavioral Group Counseling
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Locomotor and Bladder Function in Individuals With Acute Spinal Cord Injury

NCT04879862
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Epidural stimulation + Stand Training, Epidural stimulation + Step Training, Epidural stimulation + Bladder Capacity Training, Epidural stimulation + Bladder Voiding Efficiency Training
Combination Product
Lead sponsor
Claudia Angeli
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

NCT05056727
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
42
States / cities
Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

NCT00005073
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Phase 1 Interventional

Avelumab/Gemcitabine in Sarcomatoid RCC

NCT03483883
View directory record Official record
Conditions
Metastatic sRCC
Interventions
Avelumab, Gemcitabine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational

Treatment De-Intensification and Residual HIV-1 in Youth

NCT00867854
View directory record Official record
Conditions
HIV-1, HIV Infections
Interventions
Blood draw
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

NCT06412666
View directory record Official record
Conditions
Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Interventions
Aficamten, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
12 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Not applicable Interventional Results available

Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

NCT02461225
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Erchonia® FX-635™, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Up, Down, and All Around: Evaluating Mobility Devices for Young Children With Developmental Disabilities and Delays

NCT06591559
View directory record Official record
Conditions
Down Syndrome, Gross Motor Delay, Cerebral Palsy
Interventions
Permobil Explorer Mini, Portable Mobility Aid for Children (PUMA)
Device
Lead sponsor
University of Washington
Other
Eligibility
12 Months to 60 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tailoring of Vaccine-Focused Messages: Moral Foundations

NCT02851459
View directory record Official record
Conditions
Childhood Vaccinations
Interventions
Baseline Survey, Pre-intervention Survey, Morally Congruent Message, Morally Non-Congruent Message, Control Message, Post-Intervention Survey
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional

ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

NCT00300196
View directory record Official record
Conditions
Stroke, Cerebral Ischemia, Brain Infarction
Interventions
Ancrod (Viprinex), Placebo
Biological · Drug
Lead sponsor
Neurobiological Technologies
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
39
States / cities
Chico, California • Fresno, California • La Mesa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Patient-reported Outcomes of Donor Site Healing Using Different Palatal Protection Techniques

NCT06892496
View directory record Official record
Conditions
Mucosal Erosion, Gingival Recession
Interventions
Visual Analog scale (VAS) questionnaire, Vacuum-formed retainer (VFR) technique, 3-D printed acrylic resin stent (3DS) technique, Flowable resin composite stent (FRC) technique, Photographs of the patient's palate, Measuring graft dimensions, Chairside Polymer Stent
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Not applicable Interventional Results available

The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality

NCT00487162
View directory record Official record
Conditions
Hyperglycemia
Interventions
intensive glycemic control, conventional glycemic control
Procedure · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 95 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Retinal Blood Flow and Autoregulation

NCT05344274
View directory record Official record
Conditions
Glaucoma
Interventions
Indocyanine Green Angiography, Isocapnic Oxygen, Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)
Diagnostic Test · Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students

NCT07203313
View directory record Official record
Conditions
Teacher Self-efficacy for Teaching PE, Teacher PE Instruction, Student PE Enjoyment, Student Physical Activity, Student PE Satisfaction
Interventions
Digital PE teaching app
Behavioral
Lead sponsor
Saavsus, Inc.
Other
Eligibility
7 Years and older
Enrollment
1,872 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Eugene, Oregon • Springfield, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 21, 2026, 6:40 PM EDT